Assignee
CELLDEX THERAPEUTICS INC
US23 patents
Top patents by PatentIndex Score
US10633444B2Apr 28, 2020
Agonistic antibodies that bind CD40
CELLDEX THERAPEUTICS INC12 citations91
US7563876B2Jul 21, 2009
Human monoclonal antibodies to dendritic cells
CELLDEX THERAPEUTICS INC11 citations83
US10781267B2Sep 22, 2020
Methods of treating by administering anti-kit antibodies
CELLDEX THERAPEUTICS INC7 citations82
US10189907B2Jan 29, 2019
Polynucleotides encoding anti-KIT antibodies
CELLDEX THERAPEUTICS INC6 citations82
US10184007B2Jan 22, 2019
Methods of treating a kit-associated cancer by administering anti-kit antibodies
CELLDEX THERAPEUTICS INC9 citations82
US11891452B2Feb 6, 2024
Anti-kit antibodies and uses thereof
CELLDEX THERAPEUTICS INC1 citations71
US11180566B2Nov 23, 2021
Antibodies that bind human CD27 and uses thereof
CELLDEX THERAPEUTICS INC4 citations71
US10793639B2Oct 6, 2020
Methods of treating by administering anti-kit antibodies
CELLDEX THERAPEUTICS INC3 citations71
US10941201B2Mar 9, 2021
Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies
CELLDEX THERAPEUTICS INC2 citations70
US10865244B2Dec 15, 2020
Nucleic acids encoding agonistic antibodies that bind CD40
CELLDEX THERAPEUTICS INC1 citations70
US10774146B2Sep 15, 2020
Treatment of eosinophil or mast cell related disorders
CELLDEX THERAPEUTICS INC2 citations69
US9649357B2May 16, 2017
Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
CELLDEX THERAPEUTICS INC2 citations68
US11459393B2Oct 4, 2022
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
CELLDEX THERAPEUTICS INC0 citations62
US11332537B2May 17, 2022
Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
CELLDEX THERAPEUTICS INC1 citations62
US11884699B2Jan 30, 2024
Anti-KIT antibodies and uses thereof
CELLDEX THERAPEUTICS INC0 citations61
US8362214B2Jan 29, 2013
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
CELLDEX THERAPEUTICS INC3 citations61
US12297266B2May 13, 2025
Agonistic antibodies that bind human CD40 and uses thereof
CELLDEX THERAPEUTICS INC0 citations60
US11987626B2May 21, 2024
Treatment of eosinophil or mast cell related disorders
CELLDEX THERAPEUTICS INC0 citations59
US11884734B2Jan 30, 2024
Anti-MET antibodies and methods of use thereof
CELLDEX THERAPEUTICS INC0 citations55
US7316812B2Jan 8, 2008
Cells expressing anti-Fc receptor binding components
CELLDEX THERAPEUTICS INC0 citations52
US9624300B2Apr 18, 2017
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
CELLDEX THERAPEUTICS INC0 citations51
US11091559B2Aug 17, 2021
Anti-ALK antibodies and methods for use thereof
CELLDEX THERAPEUTICS INC0 citations48
US10745490B2Aug 18, 2020
Anti-ErbB antibodies and methods of use thereof
CELLDEX THERAPEUTICS INC0 citations46